RegeneRx Biopharmaceuticals, Inc. Release: Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that researchers have shown that Thymosin beta 4 (Tß4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI), indicating that Tß4 has promising therapeutic potential in patients with TBI.”

Back to news